Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: HSPD1

Summary for HSPD1

Gene information	Gene symbol	HSPD1
	Ensembl ID	ENSG00000144381
	Entrez ID	3329
	Gene name	heat shock protein family D (Hsp60) member 1
	Synonyms	GroEL\|HSP60\|SPG13
	Gene type	protein_coding
	UniProtAcc	P10809

Top

Dataset with differentially expressed gene: HSPD1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	-1.1032	2.31e-31
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	-0.263853	3.58e-30
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	0.270243	1.49e-05
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	0.681752	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.556992	7.39e-10
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.703798	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.593746	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	0.416443	8.22e-06
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.743031	3.91e-14
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	1.0295	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.755704	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.849249	0.00e+00
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	0.939268	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	pDCs	-0.951461	2.30e-02
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Plasma cells	-0.682448	2.32e-05
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	-0.289722	9.84e-05
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	-0.643394	3.78e-07
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Plasma cells	-0.596736	1.08e-40
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	-1.11289	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.274757	1.45e-14
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	pDCs	-0.638027	7.63e-04
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	0.366441	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.82349	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-1.26899	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.511662	9.25e-10
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.564771	3.04e-04
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-0.464092	7.15e-14
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.580908	3.13e-04
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.484355	1.52e-06
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.33307	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	0.429941	1.12e-11
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	0.64107	0.00e+00
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	post	Malignant cells	0.313801	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	0.623692	0.00e+00
GSE149214	PC9 cell line	Cell line	Lung cancer	EGFR-mutated non-small cell lung cancer (NSCLC)	Targeted therapy	erlotinib	NA	Malignant cells	-0.429512	1.05e-32
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.353873	4.46e-32
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.624692	1.40e-26
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	1.14994	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.385852	7.22e-42
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.507417	0.00e+00
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.538345	0.00e+00
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.363036	2.01e-15
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.537235	1.40e-45
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.469653	3.55e-25
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	0.439738	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	-0.841273	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	-0.576723	0.00e+00
GSE164897_Vem	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib	NA	Malignant cells	-0.265393	2.80e-45
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-0.598083	0.00e+00

Top

Expression of HSPD1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to HSPD1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Gene symbol	Mechanism
HSPD1	Unusual Activation of Pro-survival Pathway

Page: 1

Top

MicroRNAs (miRNA) regulating HSPD1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
HSPD1	hsa-miR-12122	98.6094	NM_002156
HSPD1	hsa-let-7c-3p	98.1899	NM_002156
HSPD1	hsa-miR-6853-3p	97.2817	NM_002156
HSPD1	hsa-miR-942-5p	95.7983	NM_002156
HSPD1	hsa-miR-10399-5p	95.6505	NM_002156
HSPD1	hsa-miR-6504-3p	95.2471	NM_002156
HSPD1	hsa-miR-8069	94.8589	NM_002156
HSPD1	hsa-miR-1-3p	92.8401	NM_002156
HSPD1	hsa-miR-613	92.8401	NM_002156
HSPD1	hsa-miR-206	92.8401	NM_002156
HSPD1	hsa-miR-4670-3p	92.6909	NM_002156
HSPD1	hsa-miR-6505-3p	92.2499	NM_002156
HSPD1	hsa-miR-494-5p	89.7545	NM_002156
HSPD1	hsa-miR-410-5p	89.7545	NM_002156
HSPD1	hsa-miR-323b-5p	89.7545	NM_002156
HSPD1	hsa-miR-4684-5p	89.3196	NM_002156
HSPD1	hsa-miR-146a-3p	88.6554	NM_002156
HSPD1	hsa-miR-190a-3p	88.1247	NM_002156
HSPD1	hsa-miR-6762-3p	87.7676	NM_002156
HSPD1	hsa-miR-4801	87.3525	NM_002156
HSPD1	hsa-miR-8062	85.9886	NM_002156
HSPD1	hsa-miR-4731-3p	83.6738	NM_002156
HSPD1	hsa-miR-27b-3p	83.1333	NM_002156
HSPD1	hsa-miR-27a-3p	83.1333	NM_002156
HSPD1	hsa-miR-9985	83.1333	NM_002156
HSPD1	hsa-miR-6512-5p	81.7454	NM_002156

Page: 1

Top

Motifs and transcription factors (TFs) regulating HSPD1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
HSPD1	jaspar__MA1933.1	SREBF2 (directAnnotation).
HSPD1	taipale_tf_pairs__MEIS1_ELF1_NTGCCGGAAGTN_CAP_repr	ELF1; MEIS1 (directAnnotation).
HSPD1	taipale_tf_pairs__ELK1_TEF_NSCGGAWNTTACGTAAN_CAP	ELK1; TEF (directAnnotation).
HSPD1	taipale_tf_pairs__HOXB2_ETV4_ACCGGAAATGAN_CAP	ETV4; HOXB2 (directAnnotation).
HSPD1	cisbp__M08198	ELF1 (directAnnotation).
HSPD1	taipale_tf_pairs__ETV2_HES7_RSCGGAANNNNNNNCACGTGNN_CAP_repr	ETV2; HES7 (directAnnotation).
HSPD1	metacluster_19.7	GMEB1; GMEB2 (inferredBy_Orthology).
HSPD1	taipale_tf_pairs__ATF4_TEF_RNMTGATGCAATN_CAP	ATF4; TEF (directAnnotation).
HSPD1	metacluster_52.11	ZNF184 (directAnnotation).
HSPD1	metacluster_56.5	HSF1; HSF1; HSF2 (directAnnotation). HSF1; HSF2; HSF4; HSF5; HSFX1; HSFX2; HSFX3; HSFX4; HSFY1; HSFY2 (inferredBy_Orthology).
HSPD1	metacluster_21.5	HOXB2; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF2; HSF2; HSF2; HSF2; HSF2; HSF2; HSF4; HSF4; HSF4 (directAnnotation). HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF2; HSF2; HSF2; HSF2; HSF4; HSF4; HSF4; HSF4; HSF5; HSF5; HSF5; HSF5; HSFX1; HSFX1; HSFX1; HSFX1; HSFX2; HSFX2; HSFX2; HSFX2; HSFX3; HSFX3; HSFX3; HSFX3; HSFX4; HSFX4; HSFX4; HSFX4; HSFY1; HSFY1; HSFY1; HSFY1; HSFY2; HSFY2; HSFY2; HSFY2 (inferredBy_Orthology).
HSPD1	metacluster_56.4	HSF1; HSF2; HSF2; HSF4 (directAnnotation).
HSPD1	taipale_tf_pairs__FLI1_CEBPD_RNCGGANNTTGCGCAAN_CAP	CEBPD; FLI1 (directAnnotation).
HSPD1	taipale_tf_pairs__TEAD4_ERG_RSCGGAAATRCC_CAP	ERG; TEAD4 (directAnnotation).
HSPD1	metacluster_21.4	HSF1; HSF1; HSF2 (directAnnotation). HSF1; HSF2; HSF4; HSF5; HSFX1; HSFX2; HSFX3; HSFX4; HSFY1; HSFY2 (inferredBy_Orthology).
HSPD1	taipale_tf_pairs__ERF_DLX2_RSCGGAANNNNNYMATTA_CAP_repr_1	DLX2; ERF (directAnnotation).
HSPD1	tfdimers__MD00465	CRX; IKZF1 (directAnnotation).
HSPD1	metacluster_56.3	HSF2 (directAnnotation).
HSPD1	taipale_tf_pairs__ERF_DLX2_RSCGGAANNNNNYMATTA_CAP_repr_2	DLX2; ERF (directAnnotation).
HSPD1	transfac_public__M00024	E2F1 (directAnnotation).
HSPD1	taipale_tf_pairs__ATF4_CEBPD_NGATGATGCAATNN_CAP	ATF4; CEBPD (directAnnotation).
HSPD1	taipale_tf_pairs__HOXB2_ETV1_ACCGGAAATGA_CAP	ETV1; HOXB2 (directAnnotation).
HSPD1	metacluster_2.8	IRF4; IRF5; IRF6; IRF9 (directAnnotation). IRF3; IRF5; IRF5; IRF6 (inferredBy_Orthology).
HSPD1	taipale_tf_pairs__ELK1_HOXA3_RSCGGTAATKR_CAP_repr	ELK1; HOXA3 (directAnnotation).
HSPD1	metacluster_141.2	E2F2; E2F3 (directAnnotation).
HSPD1	metacluster_26.10	SOX21; SOX7; SOX8 (directAnnotation).
HSPD1	metacluster_2.9	IRF2; IRF2; IRF2; PRDM1; PRDM1 (directAnnotation). PRDM1 (inferredBy_Orthology).
HSPD1	taipale_tf_pairs__CEBPG_CREB3L1_NGCCACGCAAYN_CAP_repr	CEBPG; CREB3L1 (directAnnotation).
HSPD1	taipale_cyt_meth__ZNF385D_NCGTCGCGACGN_eDBD_meth	ZNF385D (directAnnotation).
HSPD1	taipale_tf_pairs__TEAD4_ERG_RSCGGAAATRCC_CAP_repr	ERG; TEAD4 (directAnnotation).
HSPD1	taipale_tf_pairs__ELK1_EOMES_RSCGGAANNAGGYGYNA_CAP_repr	ELK1; EOMES (directAnnotation).
HSPD1	taipale_tf_pairs__TEAD4_ETV1_RSCGGAAATRCM_CAP	ETV1; TEAD4 (directAnnotation).
HSPD1	metacluster_81.7	CREB1 (directAnnotation).
HSPD1	transfac_pro__M00492	STAT1 (directAnnotation).
HSPD1	metacluster_165.3	HOMEZ; HOMEZ; HOMEZ (directAnnotation).
HSPD1	jaspar__MA0863.1	MTF1 (directAnnotation).
HSPD1	transfac_pro__M04886	ETS1 (directAnnotation).
HSPD1	c2h2_zfs__M0393	KLF9 (inferredBy_Orthology).
HSPD1	tfdimers__MD00489	IRF1; NR3C1 (directAnnotation).
HSPD1	transfac_pro__M06135	ZNF28 (directAnnotation).
HSPD1	taipale_tf_pairs__ETV2_CEBPD_RSCGGANNTTGCGYAAN_CAP_repr	CEBPD; ETV2 (directAnnotation).
HSPD1	transfac_pro__M06510	ZFP62 (directAnnotation).
HSPD1	taipale_tf_pairs__TEAD4_PITX1_RCATTCNNNNNTAATCC_CAP	PITX1; TEAD4 (directAnnotation).
HSPD1	swissregulon__hs__HSF2	HSF2 (directAnnotation).
HSPD1	hocomoco__HSF1_MOUSE.H11MO.1.A	HSF1 (inferredBy_Orthology).
HSPD1	transfac_pro__M06194	ZNF121 (directAnnotation).
HSPD1	transfac_pro__M05488	ZSCAN5B (directAnnotation).
HSPD1	metacluster_52.1	PRDM4 (directAnnotation).
HSPD1	dbtfbs__ZBTB26_HepG2_ENCSR184SVO_merged_N1	ZBTB26 (directAnnotation).
HSPD1	hocomoco__HSF1_HUMAN.H11MO.1.A	HSF1 (directAnnotation).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
HSPD1	"Copper"	DB09130	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."